- $57.30m
- $25.90m
- $4.80m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.33 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -150.26% | ||
| Return on Equity | -189.23% | ||
| Operating Margin | -1035.29% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 4.8 | 53.71 | 103.82 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Directors
- Aharon Schwartz CHM (79)
- Philip Serlin CEO (60)
- Mali Zeevi CFO (41)
- Ella Sorani VPR (49)
- Abi Vainstein-Haras VPR (42)
- Hillit Mannor Shachar VBD
- Michael Anghel DRC (82)
- Barbara-Jean Bormann DRC (56)
- Raphael Hofstein DRC (71)
- Sandra Panem DRC (74)
- Nurit Benjamini NED (54)
- Avraham Molcho NED (60)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 2nd, 2003
- Public Since
- January 30th, 2007
- No. of Employees
- 79
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 1,199,089,165
- Address
- Modi'in Technology Park, MODIIN, 7177871
- Web
- https://www.biolinerx.com/
- Phone
- +972 86429100
- Auditors
- Kesselman & Kesselman
Upcoming Events for BLRX
Similar to BLRX
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 19:04 UTC, shares in BioLine RX are trading at $0.72. This share price information is delayed by 15 minutes.
Shares in BioLine RX last closed at $0.72 and the price had moved by -33.01% over the past 365 days. In terms of relative price strength the BioLine RX share price has underperformed the S&P500 Index by -45.9% over the past year.
The overall consensus recommendation for BioLine RX is Buy. You can view the full broker recommendation list by unlocking its StockReport.
BioLine RX does not currently pay a dividend.
BioLine RX does not currently pay a dividend.
BioLine RX does not currently pay a dividend.
To buy shares in BioLine RX you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.72, shares in BioLine RX had a market capitalisation of $57.30m.
Here are the trading details for BioLine RX:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BLRX
Based on an overall assessment of its quality, value and momentum BioLine RX is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in BioLine RX is $13.75. That is 1818.25% above the last closing price of $0.72.
Analysts covering BioLine RX currently have a consensus Earnings Per Share (EPS) forecast of -$3.85 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioLine RX. Over the past six months, its share price has underperformed the S&P500 Index by -61.76%.
As of the last closing price of $0.72, shares in BioLine RX were trading -50.96% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BioLine RX PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
BioLine RX's management team is headed by:
- Aharon Schwartz - CHM
- Philip Serlin - CEO
- Mali Zeevi - CFO
- Ella Sorani - VPR
- Abi Vainstein-Haras - VPR
- Hillit Mannor Shachar - VBD
- Michael Anghel - DRC
- Barbara-Jean Bormann - DRC
- Raphael Hofstein - DRC
- Sandra Panem - DRC
- Nurit Benjamini - NED
- Avraham Molcho - NED